yingweiwo

Mitoxantrone (mitozantrone)

Alias: NSC-301739; DHAQ; CL-232325; NSC301739; 65271-80-9; Mitoxanthrone; Mitoxantron; DHAQ; Mitoxantrona; Mitoxantronum; CL 232325; NSC 301739; CL232325; Mitozantrone; Mitoxantrone HCl; Mitoxantrone dihydrchloride; US brand name: Novantrone. Foreign brand names: Mitroxone; Neotalem; Onkotrone; Pralifan.
Cat No.:V1412 Purity: ≥98%
Mitoxantrone (formerly known as NSC-301739; CL232325; Mitozantrone; Novantrone; Mitroxone; Neotalem; Onkotrone; Pralifan),the hydrochloride salt ofMitoxantrone which is an approved anticancer medication, is a potent type II topoisomerase inhibitorwith potential antitumor activity.
Mitoxantrone (mitozantrone)
Mitoxantrone (mitozantrone) Chemical Structure CAS No.: 65271-80-9
Product category: Topoisomerase
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
50mg
100mg
250mg
500mg
1g
Other Sizes

Other Forms of Mitoxantrone (mitozantrone):

  • Mitoxantrone diacetate
  • Mitoxantrone HCl (mitozantrone)
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Top Publications Citing lnvivochem Products
Purity & Quality Control Documentation

Purity: ≥98%

Product Description

Mitoxantrone (formerly known as NSC-301739; CL232325; Mitozantrone; Novantrone; Mitroxone; Neotalem; Onkotrone; Pralifan), the hydrochloride salt of Mitoxantrone which is an approved anticancer medication, is a potent type II topoisomerase inhibitor with potential antitumor activity. In HepG2 and MCF-7/wt cells, it inhibits TOPO II with IC50s of 2.0 μM and 0.42 mM, respectively. It is a proven treatment for multiple sclerosis and an anti-neoplastic for leukemia and other cancers. Through its suppression of DNA synthesis and cell cycle progression, mitoxantrone treated leukemia. It affected various immune cells, including macrophages, T cells, and B cells. The interference caused multiple DNA strand breaks (DSBs), chromatin structure changes, and other effects. It was related to TOPO-II-mediated DNA cleavage.

Biological Activity I Assay Protocols (From Reference)
Targets
PKC ( IC50 = 8.5 μM ); Topoisomerase II
ln Vitro

Mitoxantrone causes DNA fragmentation and the proteolytic cleavage of poly(ADP-ribose) polymerase (PARP), a marker of caspase activation, in every patient examined, proving that the induction of apoptosis is the cause of mitoxantrone's cytotoxic effect[1]. Mitoxantrone stimulates IkappaBalpha degradation and activates NFkappaB in the promyelocytic leukemia cell line HL60, but not in the variant cells, HL60/MX2 cells, which express a truncated alpha isoform of topoisomerase II and lack the beta isoform, leading to a different subcellular distribution.[2] In a dose-dependent manner, mitoxantrone suppresses the growth of activated PBMCs, B lymphocytes, or antigen-specific T-cell lines (TCLs) stimulated on antigen-presenting cells (APCs). At lower concentrations, mitoxantrone causes PBMCs, monocytes, and DCs to undergo apoptosis; at higher doses, however, cell lysis occurs.[3]

ln Vivo
1,4-Dihydroxy-5,8-bis(((2-[(2-hydroxyethyl) amino] ethyl)amino))-9,10-anthracenedione dihydrochloride (mitoxantrone) was tested for antitumor activity against experimental tumors in mice and the results were compared with those of seven antitumor antibiotics: adriamycin (ADM), daunomycin (DM), aclarubicin, mitomycin C (MNC), bleomycin, neocarzinostatin, and chromomycin A3. The drugs were given IP or IV, in general on days 1, 5, and 9 following tumor inoculation. Mitoxantrone given IP at the optimal dose (1.6 mg/kg/day; as a free base) produced a statistically significant number of 60-day survivors (curative effect) in mice with IP implanted L1210 leukemia. The curative effect was not observed with any of the other antibiotics. In the case of IV implanted L1210 leukemia, there was an increase in lifespan (ILS) by more than 100% in the mice following IV treatment with mitoxantrone or DM. In IP implanted P388 leukemia, the curative effect was elicited by IP treatment with mitoxantrone or MMC. In IP implanted B16 melanoma, both the curative effect and a more than 100% ILS in mice that did die were produced by IP treatment with mitoxantrone or ADM. In SC implanted Lewis lung carcinoma, mitoxantrone and ADM administered IV also showed effective antitumor activities and produced a 60% and a 45% ILS, respectively. In conclusion, mitoxantrone and ADM had a wider spectrum of antitumor activity against mouse tumors, including two leukemias and two solid tumors, than did the other drugs; however, mitoxantrone elicited higher antitumor effects than ADM on mouse leukemias, especially on L1210 leukemias. Moreover, mitoxantrone possessed much higher therapeutic indices than ADM against IP implanted P388 (optimal dose/ILS40; greater than 128 versus 15.2) and L1210 (optimal dose/ILS25; 72.7 versus 4.8) leukemias. In addition, mitoxantrone showed moderate activity against DM-resistant L1210 leukemia.[8]
Mitoxantrone temporarily reduces the growth rate of HID xenografts in mice, but PAC120 xenografts are unaffected.[4] In rats that develop spontaneous hypertension, mitoxantrone increases the severity of cardiac lesions, nephropathy, and intestinal toxicity. Mitoxantrone and iron(III) combine to form a potent 2:1 complex, wherein mitoxantrone might be functioning as a tridentate ligand.[5]
Enzyme Assay
Mitoxantrone, a new anthraquinone, showed inhibitory an effect on protein kinase C (PKC) activity. Its IC50 value was 4.4 micrograms/ml (8.5 microM), which is much lower than those of the well-known anthracyclines daunorubicin and doxorubicin, the IC50 values of which are more than 100 micrograms/ml (> 170 microM). Kinetic studies demonstrated that mitoxantrone inhibited PKC in a competitive manner with respect to histone H1, and its Ki value was 6.3 microM (Ki values of daunorubicin and doxorubicin were 0.89 and 0.15 mM, respectively), and in a non-competitive manner with respect to phosphatidylserine and ATP. Inhibition of phosphorylation by mitoxantrone was observed with various substrates including S6 peptide, myelin basic protein and its peptide substrate derived from the amino-terminal region. Their IC50 values were 0.49 microgram/ml (0.95 microM), 1.8 micrograms/ml (3.5 microM), and 0.82 microgram/ml (1.6 microM), respectively. Mitoxantrone did not markedly inhibit the activity of cyclic AMP-dependent protein kinase, casein kinase I or casein kinase II, at concentrations of less than 10 micrograms/ml. On the other hand, brief exposure (5 min) of HL60 cells to mitoxantrone caused the inhibition of cell growth with an IC50 value of 52 ng/ml (0.1 microM). In HL60 cells, most of the PKC activity (about 90%) was detected in the cytosolic fraction. When HL60 cells exposed to 10 micrograms/ml mitoxantrone for 5 min were observed with fluorescence microscopy, the fluorescence elicited from mitoxantrone was detected in the extranuclear area. These results indicated that mitoxantrone is a potent inhibitor of PKC, and this inhibition may be one of the mechanisms of antitumor activity of mitoxantrone.[7]
Cell Assay
Cell preparation and culture.[5]
PBL were collected from healthy donors in the presence of sodium citrate. Blood was defibrinated, and then mononuclear cells were isolated by centrifugation on a layer of Histopaque®. Those cell suspensions, referred to as PBL, contained 1.860.4% monocytes, as defined by CD14 expression. PBL were resuspended in Rosewell Park Memorial Institute culture medium, supplemented with 10% FCS or TCH medium, 2 mM L-glutamine, and antibiotics (penicillin 100 U/ml, streptomycin 100 mg/ml). Cultures were maintained at 378C in a humid atmosphere containing 5% CO2. During the last 8 h of incubation they were pulsed with (methyl-3 H)thymidine at 0.5 mCi/well. 3 H-TdR uptake was measured using a Packard direct beta counte after harvesting. For mixed lymphocyte reactions (MLR), the human B lymphoma cell lines RAJI and DAKIKI were used as stimulators. Stimulator cells were treated for 1 h at 378C with 25 mg/ml of mitomycin C, extensively washed, and then mixed with PBL at a ratio of 1 B cell for 10 PBL.
Measurement of nuclear apoptosis.[5]
After 3 d of culture, PHAactivated PBL were harvested. Dead cells were removed by centrifugation on a layer of Histopaque®. Viable cells (106 /ml) were washed in HBSS, and then incubated in 96-well microplates with MTX. In other experiments, PBL were either incubated for 1–24 h in the presence of MTX, and then activated with PHA for 24 to 72 h, or MTX and PHA were added together at the onset of the culture. Cell death was evaluated by fluorescence microscopy after staining with Hoechst 33342 at 10 mg/ml after previously described methods. Apoptosis was also measured by flow cytometry after addition of biotinylated annexin V and by TdT-mediated dUTP–FITC nick end labeling (TUNEL), as previously described, using reagents from Boehringer Mannheim. Samples were analyzed by flow cytrometry on a FACScan®. Nuclear fragmentation and/or marked condensation of the chromatin with reduction of nuclear size were considered as typical features of apoptotic cells. Based on these measurements, results were expressed as percentage of apoptotic cells or percentage of specific apoptosis according to the following formula: specific apoptosis 5 (T 2 C)/(100 2 C), where T stands for % of apoptotic-treated cells and C for % of apoptotic control cells. The morphological features of the cells after MTX treatment were also observed by transmission electronic microscopy, as previously described. For DNA fragmentation assay, cells were incubated in RPMI medium for 12 h with MTX, and DNA preparations were obtained and processed for electrophoresis in 2% agarose gel after previously described methods.
Animal Protocol
Mice: Mitoxantrone is tested for antitumor activity against experimental tumors in mice and the results are compared with those of seven antitumor antibiotics. The drugs are given IP or IV, in general on days 1, 5, and 9 following tumor inoculation. Mitoxantrone is given IP at the optimal dose (1.6 mg/kg/day; as a free base)[8].
1,4-Dihydroxy-5,8-bis(((2-[(2-hydroxyethyl) amino] ethyl)amino))-9,10-anthracenedione dihydrochloride (mitoxantrone) was tested for antitumor activity against experimental tumors in mice and the results were compared with those of seven antitumor antibiotics: adriamycin (ADM), daunomycin (DM), aclarubicin, mitomycin C (MNC), bleomycin, neocarzinostatin, and chromomycin A3. The drugs were given IP or IV, in general on days 1, 5, and 9 following tumor inoculation. Mitoxantrone given IP at the optimal dose (1.6 mg/kg/day; as a free base) produced a statistically significant number of 60-day survivors (curative effect) in mice with IP implanted L1210 leukemia. The curative effect was not observed with any of the other antibiotics. In the case of IV implanted L1210 leukemia, there was an increase in lifespan (ILS) by more than 100% in the mice following IV treatment with mitoxantrone or DM. In IP implanted P388 leukemia, the curative effect was elicited by IP treatment with mitoxantrone or MMC. In IP implanted B16 melanoma, both the curative effect and a more than 100% ILS in mice that did die were produced by IP treatment with mitoxantrone or ADM. In SC implanted Lewis lung carcinoma, mitoxantrone and ADM administered IV also showed effective antitumor activities and produced a 60% and a 45% ILS, respectively. In conclusion, mitoxantrone and ADM had a wider spectrum of antitumor activity against mouse tumors, including two leukemias and two solid tumors, than did the other drugs; however, mitoxantrone elicited higher antitumor effects than ADM on mouse leukemias, especially on L1210 leukemias. Moreover, mitoxantrone possessed much higher therapeutic indices than ADM against IP implanted P388 (optimal dose/ILS40; greater than 128 versus 15.2) and L1210 (optimal dose/ILS25; 72.7 versus 4.8) leukemias. In addition, mitoxantrone showed moderate activity against DM-resistant L1210 leukemia.[1]
ADME/Pharmacokinetics
Absorption, Distribution and Excretion
Poorly absorbed following oral administration
1000 L/m2
21.3 L/hr/m2 [Elderly patients with breast cancer receiving IV administration of 15-90 mg/m2]
28.3 L/hr/m2 [Non-elderly patients with nasopharyngeal carcinoma receiving IV administration of 15-90 mg/m2]
16.2 L/hr/m2 [Non-elderly patients with malignant lymphoma receiving IV administration of 15-90 mg/m2]
Metabolism / Metabolites
Hepatic
Hepatic
Half Life: 75 hours
Biological Half-Life
75 hours
Toxicity/Toxicokinetics
Toxicity Summary
Mitoxantrone, a DNA-reactive agent that intercalates into deoxyribonucleic acid (DNA) through hydrogen bonding, causes crosslinks and strand breaks. Mitoxantrone also interferes with ribonucleic acid (RNA) and is a potent inhibitor of topoisomerase II, an enzyme responsible for uncoiling and repairing damaged DNA. It has a cytocidal effect on both proliferating and nonproliferating cultured human cells, suggesting lack of cell cycle phase specificity.
Toxicity Summary
Mitoxantrone, a DNA-reactive agent that intercalates into deoxyribonucleic acid (DNA) through hydrogen bonding, causes crosslinks and strand breaks. Mitoxantrone also interferes with ribonucleic acid (RNA) and is a potent inhibitor of topoisomerase II, an enzyme responsible for uncoiling and repairing damaged DNA. It has a cytocidal effect on both proliferating and nonproliferating cultured human cells, suggesting lack of cell cycle phase specificity.
Hepatotoxicity
Chemotherapy with mitoxantrone alone is associated with serum enzyme elevations in up to 40% of patients, but these elevations are generally mild-to-moderate in severity, transient and not accompanied by symptoms or jaundice. Higher rates of liver enzyme elevations have been reported with combination chemotherapeutic regimens that include mitoxantrone. In high doses, mitoxantrone has been associated with a high rate of jaundice, but the degree of hyperbilirubinemia has been mild, transient and not associated with significant serum enzyme elevations or evidence of hepatitis. Rare instances of acute liver injury have been reported in patients taking mitoxantrone, including a single case of drug-rash with eosinophilia and systemic symptoms (DRESS). The latency to onset was 8 weeks and the pattern of serum enzyme elevations was cholestatic and later mixed. Immunoallergic features were prominent and appeared to respond to corticosteroid therapy. Other drugs were being taken and the association with mitoxantrone was not definite (Case 1). Thus, idiosyncratic and clinically apparent liver injury from mitoxantrone may occur but is quite rare.
Likelihood score: D (possible rare cause of clinically apparent liver injury).
Effects During Pregnancy and Lactation
◉ Summary of Use during Lactation
Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy, such as mitoxantrone. It might be possible to breastfeed safely during intermittent therapy with an appropriate period of breastfeeding abstinence, but the duration of abstinence is not clear. In one patient, mitoxantrone was still detectable in milk 28 days after a dose of 6 mg per square meter. Chemotherapy may adversely affect the normal microbiome and chemical makeup of breastmilk. Women who receive chemotherapy during pregnancy are more likely to have difficulty nursing their infant.
◉ Effects in Breastfed Infants
One mother received 3 daily doses of 6 mg/sq. m. of mitoxantrone intravenously along with 5 daily doses of etoposide 80 mg/sq. m. and cytarabine 170 mg/sq. m. intravenously. She resumed breastfeeding her infant 3 weeks after the third dose of mitoxantrone at a time when mitoxantrone was still detectable in milk. The infant had no apparent abnormalities at 16 months of age.
◉ Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Protein Binding
78%
References

[1]. Cancer Chemother Pharmacol. 1982;8(2):157-62.

[2]. Arthritis Rheum. 1989 Sep;32(9):1065-73.

[3]. Semin Arthritis Rheum. 1990 Dec;20(3):190-200.

[4]. Arthritis Rheum. 1989 Sep;32(9):1065-73.

[5]. J Clin Invest. 1998 Jul 15;102(2):322-8.

[6]. J Clin Invest. 1993 Dec;92(6):2675-82.

[7]. J Biochem. 1992 Dec;112(6):762-7.

[8]. Cancer Chemother Pharmacol. 1982;8(2):157-62.

Additional Infomation
Pharmacodynamics
Mitoxantrone has been shown in vitro to inhibit B cell, T cell, and macrophage proliferation and impair antigen presentation, as well as the secretion of interferon gamma, TNFa, and IL-2.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C22H28N4O6
Molecular Weight
444.48
Exact Mass
444.2
Elemental Analysis
C, 59.45; H, 6.35; N, 12.61; O, 21.60
CAS #
65271-80-9
Related CAS #
70711-41-0; 70476-82-3 (HCl); 65271-80-9; 70711-41-0 (diacetate)
PubChem CID
4212
Appearance
Brown to black solid powder
Density
1.5±0.1 g/cm3
Boiling Point
805.7±65.0 °C at 760 mmHg
Melting Point
170-174ºC
Flash Point
441.1±34.3 °C
Vapour Pressure
0.0±3.0 mmHg at 25°C
Index of Refraction
1.709
LogP
0.45
Hydrogen Bond Donor Count
8
Hydrogen Bond Acceptor Count
10
Rotatable Bond Count
12
Heavy Atom Count
32
Complexity
571
Defined Atom Stereocenter Count
0
SMILES
Cl[H].Cl[H].O=C1C2=C(C([H])=C([H])C(=C2C(C2=C(C([H])=C([H])C(=C21)N([H])C([H])([H])C([H])([H])N([H])C([H])([H])C([H])([H])O[H])N([H])C([H])([H])C([H])([H])N([H])C([H])([H])C([H])([H])O[H])=O)O[H])O[H]
InChi Key
KKZJGLLVHKMTCM-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H28N4O6/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32/h1-4,23-30H,5-12H2
Chemical Name
1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione
Synonyms
NSC-301739; DHAQ; CL-232325; NSC301739; 65271-80-9; Mitoxanthrone; Mitoxantron; DHAQ; Mitoxantrona; Mitoxantronum; CL 232325; NSC 301739; CL232325; Mitozantrone; Mitoxantrone HCl; Mitoxantrone dihydrchloride; US brand name: Novantrone. Foreign brand names: Mitroxone; Neotalem; Onkotrone; Pralifan.
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Note: This product requires protection from light (avoid light exposure) during transportation and storage.
Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO: >100 mg/mL
Water: N/A
Ethanol: N/A
Solubility (In Vivo)
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.68 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: ≥ 2.08 mg/mL (4.68 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

View More

Solubility in Formulation 3: Saline: 30 mg/mL


 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 2.2498 mL 11.2491 mL 22.4982 mL
5 mM 0.4500 mL 2.2498 mL 4.4996 mL
10 mM 0.2250 mL 1.1249 mL 2.2498 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
CTID: NCT05848687
Phase: Phase 1/Phase 2    Status: Recruiting
Date: 2024-11-25
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
CTID: NCT04797767
Phase: Phase 1    Status: Suspended
Date: 2024-11-21
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
CTID: NCT02101853
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-11-13
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
CTID: NCT04375631
Phase: Phase 1    Status: Recruiting
Date: 2024-11-04
Study of Magrolimab Combinations in Participants With Myeloid Malignancies
CTID: NCT04778410
Phase: Phase 2    Status: Completed
Date: 2024-10-08
View More

Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia
CTID: NCT03441048
Phase: Phase 1    Status: Completed
Date: 2024-10-08


CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients
CTID: NCT04195945
Phase: Phase 2    Status: Recruiting
Date: 2024-09-19
Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
CTID: NCT06429449
Phase: Phase 1    Status: Recruiting
Date: 2024-08-15
Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
CTID: NCT06007911
Phase: Phase 1    Status: Withdrawn
Date: 2024-08-13
Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation
CTID: NCT02632708
Phase: Phase 1    Status: Active, not recruiting
Date: 2024-07-25
Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
CTID: NCT02303821
Phase: Phase 1    Status: Completed
Date: 2024-07-16
Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients
CTID: NCT02400281
Phase: Phase 1/Phase 2    Status: Completed
Date: 2024-07-03
A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
CTID: NCT03164057
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-05-29
Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
CTID: NCT03860844
Phase: Phase 2    Status: Terminated
Date: 2024-05-16
Management of Radiotherapy-related Xerostomia With Green Tea and Peppermint
CTID: NCT06414161
Phase: N/A    Status: Recruiting
Date: 2024-05-16
Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia
CTID: NCT03118466
Phase: Phase 2    Status: Completed
Date: 2024-04-23
Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy
CTID: NCT03839446
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-04-18
A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML
CTID: NCT03591510
Phase: Phase 2    Status: Recruiting
Date: 2024-04-05
CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients
CTID: NCT06262438
Phase: Phase 2    Status: Recruiting
Date: 2024-02-16
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
CTID: NCT02553460
Phase: Phase 1/Phase 2    Status: Active, not recruiting
Date: 2024-01-18
Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms
CTID: NCT04196010
Phase: Phase 1    Status: Terminated
Date: 2023-12-28
Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML
CTID: NCT02626338
Phase: Phase 1/Phase 2    Status: Completed
Date: 2023-12-20
Alvocidib Biomarker-driven Phase 2 AML Study
CTID: NCT02520011
Phase: Phase 2    Status: Terminated
Date: 2023-11-15
Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia
CTID: NCT02688140
Phase: Phase 3    Status: Active, not recruiting
Date: 2023-11-02
Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia
CTID: NCT02583893
Phase: Phase 2    Status: Completed
Date: 2023-10-10
Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children
CTID: NCT05313958
Phase: Phase 2/Phase 3    Status: Recruiting
Date: 2023-07-27
Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
CTID: NCT02728050
Phase: Phase 1/Phase 2    Status: Completed
Date: 2023-07-05
GM-CLAG in Relapsed/Refractory FLT3-mutated AML
CTID: NCT05330377
Phase: Phase 1    Status: Withdrawn
Date: 2023-04-25
National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Versus Interferon Alone in Patients With Strong Risk of Progression in the Initial Phase of Multiple Sclerosis
CTID: NCT02937285
Phase: Phase 3    Status: Completed
Date: 2023-03-29
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93)
CTID: NCT00199069
Phase: Phase 4    Status: Completed
Date: 2023-03-17
Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML)
CTID: NCT00744081
Phase: Phase 2    Status: Completed
Date: 2023-03-10
Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia
CTID: NCT01842672
Phase: Phase 1/Phase 2    Status: Completed
Date: 2022-10-25
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
CTID: NCT03926624
Phase: Phase 3    Status: Unknown status
Date: 2022-10-20
Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
CTID: NCT01700946
Phase: Phase 2    Status: Completed
Date: 2022-09-28
Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
CTID: NCT02523976
Phase: Phase 2    Status: Completed
Date: 2022-08-03
A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia
CTID: NCT02200978
Phase: Phase 4    Status: Completed
Date: 2022-05-10
Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma
CTID: NCT00290511
Phase: Phase 2    Status: Completed
Date: 2022-04-22
A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia
CTID: NCT03563560
Phase: Phase 1    Status: Completed
Date: 2022-04-12
Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma
CTID: NCT00193479
Phase: Phase 2    Status: Completed
Date: 2022-03-03
International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia
CTID: NCT02724163
Phase: Phase 3    Status: Recruiting
Date: 2021-10-08
Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML
CTID: NCT03250338
Phase: Phase 3    Status: Unknown status
Date: 2021-04-30
A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic's Disease)
CTID: NCT00304291
Phase: Phase 4    Status: Completed
Date: 2020-12-28
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL
CTID: NCT01483690
Phase: Phase 1/Phase 2    Status: Terminated
Date: 2020-10-27
Brentuximab Vedotin + Re-induction Chemotherapy for AML
CTID: NCT01830777
Phase: Phase 1    Status: Completed
Date: 2020-04-14
Treatment of High Risk Adult Acute Lymphoblastic Leukemia
CTID: NCT00853008
Phase: Phase 4    Status: Completed
Date: 2020-04-07
Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma
CTID: NCT00901927
Phase: Phase 2    Status: Terminated
Date: 2020-04-03
A Study of Olaratumab (IMC-3G3) in Prostate Cancer
CTID: NCT01204710
Phase: Phase 2    Status: Completed
Date: 2019-09-20
Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's Lymphoma
CTID: NCT00169208
Phase: Phase 2    Status: Completed
Date: 2019-08-28
Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults
CTID: NCT02535806
Phase: Phase 2    Status: Terminated
Date: 2019-08-13
Clofarabine, Etoposide, and Mitoxantrone for Relapsed and Refractory Acute Leukemias
CTID: NCT00882076
Phase: Phase 1    Status: Terminated
Date: 2019-07-24
Medium Dose of Cytarabine and Mitoxantrone
CTID: NCT04024241
Phase:    Status: Unknown status
Date: 2019-07-18
Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial
CTID: NCT03735446
Phase: Phase 1    Status: Terminated
Date: 2019-06-12
Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML
CTID: NCT02306291
Phase: Phase 1/Phase 2    Status: Completed
Date: 2019-05-17
FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years
CTID: NCT00254410
Phase: Phase 2    Status: Completed
Date: 2019-05-01
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
CTID: NCT02518750
Phase: Phase 2    Status: Terminated
Date: 2019-04-03
Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone
CTID: NCT00059631
Phase: Phase 1    Status: Completed
Date: 2018-11-15
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
CTID: NCT01522443
Phase: Phase 3    Status: Terminated
Date: 2018-05-23
Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies
CTID: NCT02419755
Phase: Phase 2    Status: Terminated
Date: 2018-03-07
Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
CTID: NCT02198482
Phase: Phase 2    Status: Terminated
Date: 2018-02-28
Phase I Study of Mitoxantrone and Etoposide Combined With Hydroxychloroquine, for Relapsed Acute Myelogenous Leukemia
CTID: NCT02631252
Phase: Phase 1    Status: Terminated
Date: 2018-02-23
-----------
A Phase 2, Randomized, Biomarker-driven, Clinical Study in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with an Exploratory Arm in Patients with Newly Diagnosed High-Risk AML and Exploratory
CTID: null
Phase: Phase 2    Status: Prematurely Ended
Date: 2017-10-10
A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia
CTID: null
Phase: Phase 3    Status: Completed
Date: 2017-06-19
A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents
CTID: null
Phase: Phase 3    Status: Completed
Date: 2017-03-17
A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation
CTID: null
Phase: Phase 3    Status: Ongoing, GB - no longer in EU/EEA, Completed
Date: 2016-04-20
Study Protocol LAM 2013/01
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2015-02-04
A Phase 3 Open-Label Randomized Study of Quizartinib Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplant (HSCT) Consolidation.
CTID: null
Phase: Phase 3    Status: Ongoing, Completed
Date: 2014-06-18
A PHASE III MULTICENTER, RANDOMIZED STUDY COMPARING CONSOLIDATION WITH (90)YTTRIUM-LABELED IBRITUMOMAB TIUXETAN (ZEVALIN®) RADIOIMMUNOTHERAPY VS AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA (FL) AGED 18-65 YEARS
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2013-10-08
NOPHO-DBH AML 2012 Protocol
CTID: null
Phase: Phase 3    Status: Trial now transitioned, Ongoing
Date: 2013-01-22
Response-Adapted Sequential Azacitidine And Chemotherapy in Patients > 60 Years Old With Newly Diagnosed AML Eligible for Chemotherapy and allogeneic hematopoietic cell transplantation: A Multicentre Phase I/II study of the East German Hematology and Oncology Study Group (OSHO)
CTID: null
Phase: Phase 1, Phase 2    Status: Completed
Date: 2012-08-31
A Phase 3, randomized, double-blind, controlled trial of cabozantinib (XL184) vs. mitoxantrone plus prednisone in men with previously treated symptomatic castration-resistant prostate cancer
CTID: null
Phase: Phase 3    Status: Completed
Date: 2012-07-11
An Open-label, Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigator’s Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)
CTID: null
Phase: Phase 3    Status: Completed
Date: 2012-06-13
A Randomized Phase 2 Study of Human Anti-PDGFRα Monoclonal Antibody IMC-3G3 plus Mitoxantrone plus Prednisone or Mitoxantrone plus Prednisone in Metastatic Castration-Refractory Prostate Cancer (CRPC) Following Disease Progression or Intolerance on Docetaxel-based Chemotherapy.
CTID: null
Phase: Phase 2    Status: Completed
Date: 2010-10-20
Dutch-Belgian pediatric AML protocol for children with newly diagnosed acute myeloid leukemia, based on the NOPHO-AML 2004 study
CTID: null
Phase: Phase 3    Status: Completed
Date: 2010-05-04
A phase Ib, open-label, multi-center dose-finding study of oral panobinostat (LBH589) in combination with ara-C and mitoxantrone as salvage therapy for refractory or relapsed acute myeloid leukemia
CTID: null
Phase: Phase 1, Phase 2    Status: Completed
Date: 2010-01-08
Phase II Trial of Combined Immunochemotherapy with
CTID: null
Phase: Phase 2    Status: Completed
Date: 2009-12-07
MITOXANTRONE/GLATIRAMER ACETATE COMBINED TREATMENT IN THE THERAPY OF SECONDARY-PROGRESSIVE MULTIPLE SCLEROSIS
CTID: null
Phase: Phase 3    Status: Prematurely Ended
Date: 2009-07-30
Brief induction chemoimmunotherapy with Rituximab + Bendamustine + Mitoxantrone followed by Rituximab in elderly patients with advanced stage previously untreated follicular lymphoma
CTID: null
Phase: Phase 2    Status: Completed
Date: 2009-07-20
TREATMENT STUDY FOR CHILDREN AND ADOLESCENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2009-07-16
Attenuated dose Rituximab with ChemoTherapy In CLL:
CTID: null
Phase: Phase 4    Status: GB - no longer in EU/EEA
Date: 2009-06-25
A Randomized Phase III study comparing conventional chemotherapy to low dose total body irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors as consolidation therapy for older Patients with AML in first Complete Remission.
CTID: null
Phase: Phase 3    Status: Prematurely Ended, Completed
Date: 2009-03-26
A Randomized, Risk and Age Adapted Comparison of the Dose-Dense Regimen S-HAM (sequential high dose cytosine arabinoside and mitoxantrone) versus Standard Double Induction for Initial Chemotherapy of Adult Patients with Acute Myeloid Leukemia
CTID: null
Phase: Phase 3    Status: Completed
Date: 2009-03-10
An exploratory phase IIa study to evaluate the safety and immunological effects of intravenous interferonβ-1a (IFNβ-1a, Rebif®) therapy in the induction of tolerance to IFNβ in MS patients with neutralising antibodies (NAbs) to subcutaneous IFNβ-1a (Rebif® or Avonex®)
CTID: null
Phase: Phase 2    Status: Prematurely Ended
Date: 2009-02-16
ADMIRE: Does the ADdition of Mitoxantrone Improve REsponse
CTID: null
Phase: Phase 4    Status: GB - no longer in EU/EEA
Date: 2009-02-09
A Phase 1b/2 Study to Assess the Safety and Efficacy of AMG 102 in Combination with
CTID: null
Phase: Phase 1, Phase 2    Status: Prematurely Ended, Completed
Date: 2009-01-05
An Open-Label, Randomized, Phase 3 Study of Inotuzumab Ozogamicin (CMC-544) Administered in Combination With Rituximab Compared to a Defined Investigator’s Choice Therapy in Subjects With Relapsed or Refractory, CD22- Positive, Follicular B-Cell Non Hodgkin’s Lymphoma
CTID: null
Phase: Phase 3    Status: Prematurely Ended, Completed
Date: 2008-04-25
Klassische Konditionierung immunologischer Reaktionen bei Patienten mit Multipler Sklerose während Mitoxantrontherapie
CTID: null
Phase: Phase 4    Status: Completed
Date: 2007-12-12
A Phase II Study of PHA-739358 in Patients with Metastatic Hormone Refractory Prostate Cancer.
CTID: null
Phase: Phase 2    Status: Completed
Date: 2007-11-29
HIGH-DOSE SEQUENTIAL CHEMOTHERAPY AND RITUXIMAB (R-HDS) IN HIV+ PATIENTS WITH NON-HODGKIN LYMPHOMA (NHL) REFRACTORY OR RELAPSED AFTER 1st LINE TREATMENT
CTID: null
Phase: Phase 2    Status: Prematurely Ended
Date: 2007-10-19
A randomised phase III study to compare arsenic trioxide (ATO) combined to ATRA versus standard ATRA and anthracycline-based chemotherapy (AIDA regimen) for newly diagnosed, non high-risk acute promyelocytic leukemia
CTID: null
Phase: Phase 3    Status: Completed
Date: 2007-07-10
A Phase 2 Multicenter, Open-label Study of CNTO 328 (Anti-IL-6 Monoclonal Antibody) in Combination with Mitoxantrone versus Mitoxantrone in Subjects with Metastatic Hormone-Refractory Prostate Cancer (HRPC)
CTID: null
Phase: Phase 2    Status: Completed
Date: 2007-05-23
A Randomized, Open Label Multi-Center Study of XRP6258 At 25 mg/m2 in Combination With Prednisone Every 3 Weeks Compared To Mitoxantrone in Combination With Prednisone For The Treatment of Hormone Refractory Metastatic Prostate Cancer Previously Treated With A Taxotere®-Containing Regimen
CTID: null
Phase: Phase 3    Status: Completed
Date: 2006-11-29
Exploratory trial to evaluate the risk-benefit ratio of the use of mitoxantrone in patients under treatment with high dose interferon-beta-1a for relapsing-remitting or relapsing secondary progresive multiple sclerosis with high activity.
CTID: null
Phase: Phase 2    Status: Ongoing
Date: 2006-09-08
Curative and palliative treatment of adults aged > 60 years with AML.A randomised trial by OSHO on the role of (1) early intensification {OSHO protocol} vs. common standard arm of German AML Intergroup Study, (2) allografting as consolidative immunotherapy vs. a second consolidation course in elderly patients,(3) prospective evaluation of the decision between curative and palliative treatment-intention.
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2006-03-08
Phase III multicentric IIL study, three randomized arms (R-CVP vs R-CHOP vs R-FM),for treatment of patients with stage II-IV follicular lymphoma
CTID: null
Phase: Phase 3    Status: Completed
Date: 2006-01-30
A phase III, multicentric randomized study for the treatment of young patients with unfavorable prognosis Diffuse Large Cell B Lymphoma IPI 2-3 . Dose-dense chemotherapy Rituximab +/- intensive and high-dose chemo-immunotherapy with autologus pheripherical staminal cells.
CTID: null
Phase: Phase 3    Status: Completed
Date: 2006-01-20
Treatment protocol for relapsed anaplastic large cell lymphoma of childhood and adolescence
CTID: null
Phase: Phase 3    Status: Completed
Date: 2005-12-23
International Collaborative Treatment Protocol for the Infants Under One Year with Acute Lymphoblastic or Biphenotypic Leukemia
CTID: null
Phase: Phase 3    Status: Ongoing, Completed
Date: 2005-11-24
A pilot multi-centre randomised controlled trial of sequential treatment with Mitoxantrone and Glatiramer Acetate vs. Interferon Beta-1a in early active relapsing remitting Multiple Sclerosis.
CTID: null
Phase: Phase 4    Status: Completed
Date: 2005-07-26
MULTI-CENTRE, RANDOMISED, PHASE III TRIAL COMPARING HIGH DOSE SEQUENTIAL CHEMOTHERAPY hds WITH RITUXIMAB AND AUTOLOGOUS PERIPHERAL BLOOD PROGENITUR ALL TRANSPLANTION VERSUS 2- WEEKLY CHOP WITH RITUXIMAB AS FRONT LINE THERAPY OF HIGH RISK PATIENT WITH DIFFUSE LARGE B- CELL NON HODGKIN LYMPHOMA
CTID: null
Phase: Phase 3    Status: Completed
Date: 2005-04-12
A multicentre, phase III, open-label, randomised study in patients with advanced follicular lymphoma evaluating the benefit of maintenance therapy with Rituximab (MabThera®) after induction of response with chemotherapy plus Rituximab in comparison with no maintenance therapy
CTID: null
Phase: Phase 3    Status: Completed
Date: 2005-02-22
MULTICENTTRIC, NATIONAL, SINGLE BLIND,CONTROLLED IN PARALLEL GROUP TO EVALUATE THE SAFETY AND EFFICACY OF THE SEQUENTIAL COMBINATION OF MITOXANTRONE AND BETA INTERFERON REBIF 44 mcg X 3 TIMES WEEKLY IN PATIENTS AFFECTED BY MULTIPLE SCLEROSIS, IN THE FIRST STEP OF THE DISEASE
CTID: null
Phase: Phase 3    Status: Ongoing, Completed
Date: 2004-11-19
Evaluation of the intensification of post-remissional therapy in the treatment of high-risks adult Acute Lymphoblastic Leukemia and monitoring of the minimal residual disease
CTID: null
Phase: Phase 3    Status: Completed
Date: 2004-11-08
Pixantrone (BBR 2778) versus Other Chemotherapeutic Agents for Third-line Single Agent Treatment of Patients with Relapsed Aggressive Non-Hodgkin’s Lymphoma: A Randomized, Controlled, Phase III Comparative Trial
CTID: null
Phase: Phase 3    Status: Ongoing, Prematurely Ended, Completed
Date: 2004-11-02
IntReALL HR 2010
CTID: null
Phase: Phase 2    Status: Trial now transitioned, Ongoing, Prematurely Ended
Date:

Contact Us